(Amended) The composition of claim 59, wherein said cytokine comprises GM-CSF.

REMARKS

The above amendments are made solely to remove reference to non-elected subject matter. The Commissioner is authorized to charge any additional fees due by way of this Amendment, or credit any overpayment to our Deposit Account No. 19-1090.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version With Markings to Show Changes Made."

Following this amendment, Claims 1, 6, 7, 47-54, and 56-60 are under examination. Favorable consideration of the present application in view of the above amendment is respectfully requested.

Respectfully submitted,

Alexander Gaiger et al.

Seed Intellectual Property Law Group PLLC

Julie A Urvater, Ph.D., Patent Agent

Registration No. 50,461

Enclosure:

Postcard

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

D:\NrPortbl\iManage\JUDYD\322850_1.DOC

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 51 and 60 have been amended as follows:

- 51. (Amended) The composition of claim 50, wherein said cytokine is selected from the group consisting of comprises GM-CSF-and Flt3-ligand.
- 60. (Amended) The composition of claim 59, wherein said cytokine is selected from the group consisting of comprises GM-CSF-and Flt3-ligand.